Egle Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Egle Therapeutics - overview
Established
2020
Location
Suresnes, -, France
Primary Industry
Biotechnology
About
Egle Therapeutics SAS, based in Paris, France, is a biotechnology company focused on developing innovative therapies that engage regulatory T cells to treat cancer and autoimmune diseases. Founded in 2020 in Paris, France, Egle Therapeutics specializes in therapies targeting regulatory T cells (Tregs). Egle Therapeutics specializes in the development of innovative therapies targeting regulatory T cells (Tregs) for cancer and autoimmune diseases. Their lead products include EGL-001, currently in clinical trials for oncology (NCT06622486), and EGL-003, which has completed IND-enabling studies and plans to enter Phase I trials in 2025.
The company employs a proprietary discovery platform that utilizes multi-omics analyses and bioinformatics to identify therapeutic Treg targets, focusing on markets in North America and Europe. Their revenue model encompasses B2B transactions with biopharmaceutical companies and research organizations, leading to funding for clinical development in exchange for rights to develop therapies. This structure also includes milestone payments and royalties on future product sales as the company advances its lead products. In March 2026, Egle Therapeutics raised EUR 8 million in grant funding from Horizon Europe.
Current Investors
EQT Life Sciences, Takeda Ventures, Bpifrance Investissement
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.egle-tx.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Egle Therapeutics - financials
| Fiscal Year Ended | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|
| Revenue (USD) | - | - |
| % Revenue Growth (YoY) | - | - |
| EBITDA (USD) | - | - |
| Operating Income (USD) | - | - |
| Operating Margin | - | - |
| % EBITDA Margin | - | - |
| NET Income (USD) | - | - |
| % Net Margin | - | - |
Egle Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.